The Othala Method
Othala — Inheritance, Foundation, Sovereign Territory
A clinical method for interpreting a woman’s biology — grounded in peer-reviewed evidence, the staging frameworks ratified by the medical consensus, and female-specific reference ranges. The Othala Method is how AION Atelier interprets the biology of every woman who completes her Baseline: her stage identified, her Archetype derived, her Baseline Analysis produced from the inheritance of the literature rather than the shortcuts of general practice.
Section II STRAW+10 The Staging
The Gold-Standard Staging Of The Reproductive Transition
The Stages of Reproductive Aging Workshop +10 is the international clinical staging system for female reproductive aging — the framework the medical consensus has ratified and the one The Othala Method inherits. It divides the transition into five stages rather than the three-option pre · peri · post simplification used in most general practice. Every reader is staged against this framework, because a Baseline Analysis that collapses her stage also collapses the clinical interpretation it produces.
II · The Architecture
Six Pillars, Read Together.
Integrated, not siloed. The specific Baseline Analysis each woman receives depends on her stage, her Archetype, and her answers.
I.
Hormonal
II.
Cardiovascular
III.
Metabolic
IV.
Inflammatory
V.
Nervous System
VI.
Epigenetic
Each pillar is read against the female body, at the stage she is actually in.
How your Analysis is produced.
Four inputs are integrated by a clinical reasoning framework grounded in the peer-reviewed literature on women’s longevity biology. The framework is calibrated. The output is personal. The logic is described below; the calibration itself is proprietary.
Stage
Where you sit on the STRAW+10 reproductive arc — from late reproductive through established postmenopause. Five stages, not three. Determines which biological reference ranges apply.
Archetype
One of six derived profiles — Rising Tide, Threshold, Quiet Revolution, Long Arc, Quiet Alarm, Architect. Surfaced from your answer constellation through weighted multi-variable scoring. You do not choose it; it emerges.
Signature
Your symptom constellation as you reported it — the texture of what you are experiencing, beyond the categories of stage and archetype. The framework reads patterns, not declarations.
Literature
The peer-reviewed evidence base mapped to your stage and archetype — STRAW+10, the SWAN Study, perimenopausal endothelial decline, female-specific reference ranges, and the longitudinal women’s health literature.
The Synthesis These four inputs combine within a proprietary clinical reasoning framework to produce an Analysis specific to your biology, your stage, and the decade ahead.
The calibration.
Reference ranges — female-stratified.
The Master Biomarker Registry contains fifty-one biomarkers across nine clinical categories — hormonal, cardiovascular, metabolic, inflammatory, hepatic, renal, thyroid, bone & connective, and epigenetic.
Each biomarker is stratified by STRAW+10 stage where clinically meaningful: pre-menopausal, peri-menopausal, and post-menopausal optimal ranges are defined separately rather than collapsed into a single sex-agnostic average.
Every range is sourced from peer-reviewed literature, with primary sources documented per biomarker.
Archetype derivation — weighted, multi-variable.
Your archetype is derived from your answer constellation across the intake. The framework uses weighted multi-variable scoring with internal calibration rules that determine which archetype best fits your biological pattern.
You do not choose your archetype. It emerges from your answers. The variables, weightings, and tiebreaker logic are calibrated against the archetype literature and are proprietary to AION Atelier.
What is published: the six archetypes themselves, the literature they draw on, and the principles of multi-variable derivation. What is locked: the specific calibration.
tracked
categories
stages
archetypes
What this is not.
A methodology is defined as much by what it refuses to do as by what it claims. The Baseline Analysis is educational. It is not a substitute for clinical care.
This is not a diagnostic tool.
The Analysis does not diagnose disease, condition, or disorder. It does not interpret your case clinically. It maps your stage, your archetype, and the biomarkers worth tracking — the educational reading of your biology, not the clinical interpretation of it.
This is not a substitute for medical care.
The Analysis is designed to sit alongside your physician relationship, not replace it. We do not prescribe, treat, or advise on treatment decisions. Many readers share their Analysis with their clinician as a starting point for a more informed conversation.
This does not assess hormone therapy.
The Analysis does not evaluate whether your current hormone therapy is working, nor does it recommend whether you should begin or end hormone therapy. These are clinical decisions for you and your prescribing physician.
This is not for women in active treatment.
The Baseline is not the right starting point if you are currently in active treatment for a serious medical or mental health condition — including cancer care, mental health crisis, or eating disorder treatment — or if you are pregnant or nursing. In those cases, we recommend consulting your physician directly.
This framework is calibrated, not absolute.
The Othala Method is grounded in the current peer-reviewed literature. The literature evolves. Reference ranges are revised. Archetype calibrations are refined. The methodology is versioned, not fixed.
The most careful intelligence comes with the clearest boundaries.
Authorship, citation, and version.
The Othala Method is compiled from the peer-reviewed literature on women’s longevity biology and structured around the STRAW+10 staging framework.
Pending.
The methodology is open to peer review by NAMS-certified menopause clinicians, ob-gyn specialists, and the broader women’s longevity research community.
To request the full research document for review, contact the editors.
The methodology is grounded in the peer-reviewed literature on women’s longevity biology, with foundational frameworks drawn from STRAW+10, the SWAN Study, and the longitudinal women’s health literature. The Master Biomarker Registry tracks fifty-one biomarkers, each calibrated against primary clinical sources.
Full reference document available on request.